Stability considerations for drug-device combination products-21 CFR part 4 update
Abstract Combination products are therapeutic and diagnostic products that include two or more of the following: drug, biologic, and device. These products are needed for enhanced clinical outcomes and have more than one Mode of Action (MOA). Therefore, they require a more complex regulatory pathway...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
SpringerOpen,
2023-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|